Rare Community Profiles: Volv’s Innovative Approach Harnesses the Power of AI for Rare Disease Detection
source: pixabay.com

Rare Community Profiles: Volv’s Innovative Approach Harnesses the Power of AI for Rare Disease Detection

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Continue Reading Rare Community Profiles: Volv’s Innovative Approach Harnesses the Power of AI for Rare Disease Detection
Rare Community Profiles: From the Virtual Fun Run & Walk to Mental Health Support: How Jack Johnson of FSIG is Working to Improve the Lives of All People with Fabry Disease
source: shutterstock.com

Rare Community Profiles: From the Virtual Fun Run & Walk to Mental Health Support: How Jack Johnson of FSIG is Working to Improve the Lives of All People with Fabry Disease

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: From the Virtual Fun Run & Walk to Mental Health Support: How Jack Johnson of FSIG is Working to Improve the Lives of All People with Fabry Disease
Elfabrio Now Approved for Adults with Fabry Disease
https://pixabay.com/en/youth-active-jump-happy-sunrise-570881/

Elfabrio Now Approved for Adults with Fabry Disease

On May 10, 2023, reports EMPR, the U.S. FDA approved Elfabrio (pegunigalsidase alfa-iwxj) for adults who are living with Fabry disease. Developed by Protalix Biotherapeutics in conjunction with Chiesi Global…

Continue Reading Elfabrio Now Approved for Adults with Fabry Disease
After 10 Children with Rare Diseases died, Indian MP Varnum Gandhi Warns that more Children are in Danger
source: unsplash.com

After 10 Children with Rare Diseases died, Indian MP Varnum Gandhi Warns that more Children are in Danger

  New Delhi: Recent headlines in the Hindustan Times highlighted a letter written by the leader of the Bharatiya Janata Party, Varnum Gandhi, to Health Minister Mansukh Mandaviya urging him…

Continue Reading After 10 Children with Rare Diseases died, Indian MP Varnum Gandhi Warns that more Children are in Danger
Evaluating ST-920 for Fabry Disease: An Interview with Sangamo’s Bettina Cockroft, MD, MBA
Photo courtesy of Sangamo

Evaluating ST-920 for Fabry Disease: An Interview with Sangamo’s Bettina Cockroft, MD, MBA

The European Society for Gene and Cell Therapy (ESGCT) recently held its Annual Congress from October 11-14, 2022. During the ESGCT Congress, various stakeholders discussed data, trends, and new research…

Continue Reading Evaluating ST-920 for Fabry Disease: An Interview with Sangamo’s Bettina Cockroft, MD, MBA
Phase 2 Fabry Disease Clinical Trial Has Been Stopped Due to Negative Outcomes
source: pixabay.com

Phase 2 Fabry Disease Clinical Trial Has Been Stopped Due to Negative Outcomes

Avrobio has just announced that they will be stopping work on their investigative gene therapy for Fabry disease based on unexpected and disappointing results from a Phase 2 clinical trial.…

Continue Reading Phase 2 Fabry Disease Clinical Trial Has Been Stopped Due to Negative Outcomes
14th ICIEM Conferences: Data to be Presented on Fabry Disease and Gaucher Disease Trials
Pixabay

14th ICIEM Conferences: Data to be Presented on Fabry Disease and Gaucher Disease Trials

From November 21st until the 23rd, medical professionals and others involved in the metabolic field will come together for the 14th International Congress of Inborn Errors of Metabolism (ICIEM). It…

Continue Reading 14th ICIEM Conferences: Data to be Presented on Fabry Disease and Gaucher Disease Trials
EC Approves Galafold for Adolescent Fabry Disease with an Amenable Mutation
Source: https://unsplash.com/photos/ZHys6xN7sUE

EC Approves Galafold for Adolescent Fabry Disease with an Amenable Mutation

On August 2, 2021, biotechnology company Amicus Therapeutics ("Amicus") shared that its oral treatment Galafold (migalastat) was approved by the European Commission (EC) for the treatment of adolescent patients (ages…

Continue Reading EC Approves Galafold for Adolescent Fabry Disease with an Amenable Mutation